{"filing":{"accession_number":"0000875320-26-000264","cik":"0000875320","ticker":"VRTX","company_name":"VERTEX PHARMACEUTICALS INC / MA","form":"8-K","filing_date":"2026-09-01","report_date":"2026-08-27","primary_document":"vrtx-20260827.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000264/vrtx-20260827.htm"},"events":[{"id":31002,"run_id":28431,"accession_number":"0000875320-26-000264","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Jonathan Poole was appointed as Executive Vice President and Chief Financial Officer effective January 1, 2027. While the disclosure also mentions Charles F. Wagner, Jr. ceasing to serve as CFO, the principal action disclosed is Poole's appointment to a C-suite financial role at a major pharmaceutical company. The filing details his compensation arrangements ($750,000 base salary, 90% target bonus) and change-of-control protections, which are typical components of executive appointment disclosures under Item 5.02(a) and (e).","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33770,"accession_number":"0000875320-26-000264","item_number":"5.02","item_title":"Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Jonathan Poole was appointed as Executive Vice President and Chief Financial Officer effective January 1, 2027. While the disclosure also mentions Charles F. Wagner, Jr. ceasing to serve as CFO, the principal action disclosed is Poole's appointment to a C-suite financial role at a major pharmaceutical company. The filing details his compensation arrangements ($750,000 base salary, 90% target bonus) and change-of-control protections, which are typical components of executive appointment disclosures under Item 5.02(a) and (e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:27:25.960049+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33770,"accession_number":"0000875320-26-000264","item_number":"5.02","item_title":"Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Jonathan Poole was appointed as Executive Vice President and Chief Financial Officer effective January 1, 2027. While the disclosure also mentions Charles F. Wagner, Jr. ceasing to serve as CFO, the principal action disclosed is Poole's appointment to a C-suite financial role at a major pharmaceutical company. The filing details his compensation arrangements ($750,000 base salary, 90% target bonus) and change-of-control protections, which are typical components of executive appointment disclosures under Item 5.02(a) and (e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T20:27:25.960049+00:00","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-09-01"}]}